|Bid||0.4400 x 3068000|
|Ask||0.4450 x 2473100|
|Day's Range||0.4400 - 0.4550|
|52 Week Range||0.1350 - 0.6300|
|Beta (5Y Monthly)||1.32|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.08|
SYDNEY, AUSTRALIA, April 16, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,155,055 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&D activities conducted in the 2020 fiscal year, mainly related to the Company’s TACTI-mel and TACTI-002 clinical study using its lead compound eftilagimod alpha (“efti” or “IMP321”), conducted in Australia. This follows approval from AusIndustry of Immutep’s application for an Advance/Overseas Finding. Due to the Advance Finding, both Immutep’s Australian and overseas research and development activities related to the TACTI-002 Australian sites are eligible for the R&D Tax Incentive for a period of three years to 30 June 2021. Immutep will apply the funding towards furthering its current active clinical trial programs for its lead product, eftilagimod alpha. About ImmutepImmutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer, infectious disease, and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners. Further information can be found on the Company’s website www.immutep.com or by contacting: Australian Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406 759 268; firstname.lastname@example.org U.S. Media:Tim McCarthy, LifeSci Advisors+1 (212) 915.2564; email@example.com
We’ve reached a tipping point in history where the devastating impact that stress has on our minds, bodies, communities and environment simply can’t be denied. Stress is widely considered the “social toxin of today” by doctors and medical experts; it is responsible for an estimated 75 to 90% of all doctors visits. With reports of loneliness and digital addiction at an all time high, stress is wreaking havoc on our physical and mental health. Prima is a whole body care brand dedicated to the everyday pursuit of a life with less stress. This whole body care brand (for the skin, body and mind) believes that hemp CBD and active functional ingredients from plants can support stress of the skin, body and mind, and also provide many other functional benefits. Prima isn’t a beauty brand, but a whole body care brand that understands holistic health and how to create DTC solutions that are accessible, innovative, clinically-validated and industry-defining. Recently they launched two new product supplements, No Worries and Sleep Tight, made with active botanical ingredients and the highest quality hemp CBD to target two of the most pressing issues we face: stress and sleep. Prima uses an organically grown broad spectrum hemp extract from a single-origin network of family farms and makes products with 0% THC. Prima was founded by three clean beauty veterans who have spent their careers helping people understand the potentially harmful industrial compounds in our everyday products: from phthalates in nail polish to heavy metals in antiperspirant and carcinogens in baby shampoo. Prima’s CEO and Co-Founder Christopher Gavigan founded The Honest Company in 2011 and started working on the idea in 2008, long before “clean” was a mainstream word used to describe products. When Christopher Gavigan, Laurel Angelica Myers (an Honest Company alum) and Jessica Assaf (cannabis industry veteran with a Harvard MBA), they decided to take a new approach to “clean”, and build a brand and Certified B Corp. focused on CBD. Society has shifted, and rather than creating products without the use of toxins, they are creating products to provide solutions for the biggest toxin of our time: stress. No Worries and Sleep Tight are the culmination of over two years of planning and 18 months of research and development, which is expected in the supplements category to ensure the health and safety of ingestible products. These supplements combine Prima’s organically-grown hemp CBD (sourced from a network of family farms in Oregon) with clinically-validated active botanical ingredients, to target stress at its source. When the Prima team heard from their customers that The Daily, their bestselling CBD softgel, was successfully supporting sleep and overall stress response, they decided to expand their offerings to include formulations with a baseline of concentration of CBD and specialized, synergistic plant-based actives that have been clinically studied for their role in improving stress and sleep specifically. No Worries features CBD, Holy Basil, Ashwagandha and Saffron, and Sleep Tight features CBD, 5-HTP, Gaba and Passionflower. After taking No Worries for a few days, I definitely notice an enhancement in my overall mood, and I’m feeling much calmer during the day. When I take Sleep Tight before bed, I have an uninterrupted sleep, usually with clear dreams. Prima hopes these products make it easier for consumers to easily access better days and nights, from the comfort of their own home, without a visit to the doctor (or a stress-inducing WebMD search). Learn more about Prima at: www.prima.co See more from BenzingaClick here for options trades from BenzingaTopps Announces MLB NFTs: What Investors And Collectors Should KnowThis Day In Market History: The Yahoo! IPO© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Immutep Limited reported that the U.S. Food and Drug Administration (FDA) granted the Fast Track designation to eftilagimod alpha in the treatment of recurring or metastatic head and neck squamous cell carcinoma (HNSCC). The Fast Track designation is given to drugs that fill an unmet medical need to expedite their development and approval. It ensures that the company in question and the FDA will work closely together at every step of the process.